For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Patent Rows Don’t Stop Generic Players; Single Entries, AG Non-Launches Seen in June Listing
June 17, 2022
- Nihon Medi-Physics Launches AMED-Funded Project to Develop Antibody-RI Conjugates
June 16, 2022
- Ajovy Auto-Injector Approved in Japan: Otsuka
June 16, 2022
- Shionogi to Expand Access for Cefiderocol in Low- and Middle-Income Nations
June 16, 2022
- Asahi Kasei Snags Rights to Tsukuba Upstart’s CKD Drug Candidate
June 15, 2022
- Daiichi Sankyo Kicks Off PIII to Test ADC Follow-Up for Triple-Negative Breast Cancer
June 15, 2022
- Sanofi Set for Dupixent’s Pediatric Eczema Filing in Japan after Positive Data
June 15, 2022
- Otsuka Ties Up with xFOREST on RNA Structure-Targeted Drug Discovery
June 14, 2022
- Authorized Generics Gain Ground amid Quality Woes, Candesartan AG Share Up 10 Points
June 14, 2022
- Quizartinib Cuts Risk of Death by 22.4% in 1st Line AML: Daiichi Sankyo
June 14, 2022
- FDA Accepts Resubmission for Santen/Ube’s Glaucoma Med
June 13, 2022
- Kasper Bødker Mejlvang Tapped as New Novo Japan Chief
June 13, 2022
- AstraZeneca Japan Chief Stefan Woxström Standing Down, Successor Yet to Be Named
June 13, 2022
- Takeda’s Dengue Vaccine Proves 4.5-Year Protection
June 10, 2022
- Chugai Challenges Ruling in Method-of-Use Patent Case for Edirol
June 10, 2022
- AstraZeneca Files COVID Antibody in Japan, Seeks Special Approval
June 9, 2022
- All FAD Agents in Japan to Be Discontinued as Kyowa Hakko Bio Quits API Production
June 9, 2022
- Gilead Japan Flaunts Unique Pipeline Candidates for HIV, COVID, Oncology
June 9, 2022
- Lilly/Daiichi Sankyo’s Migraine Med Reyvow Hits Japan Market
June 9, 2022
- Eisai Ups Earnings Guidance for FY2022
June 9, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…